Finally, patients with high-risk, early HER2+ breast cancer receiving neoadjuvant atezolizumab in combination with dose-dense doxorubicin plus cyclophosphamide, followed by paclitaxel, trastuzumab, and pertuzumab enrolled in the Phase III IMpassion050 trial failed to experience pathological complete responses at increased rates compared with similarly treated women who received placebo instead of atezolizumab, neither in the intention-to-treat population nor among subjects with PD-L1+ tumors, ultimately leading to study discontinuation because of an unfavorable risk‒benefit ratio [118]. Here, CD274 is linked to breast carcinoma.